Bank of America spends more than $250 million a year covering GLP-1 weight loss drugs for its employees, CEO Brian Moynihan told CNBC on Wednesday, saying the rapidly rising cost is a worthwhile investment in his workforce.The company sets aside more than $2 billion a year on healthcare overall for BofA’s roughly 211,000 employees, meaning that GLP-1 medications alone now account for roughly 13% o…
Bank of America CEO: GLP-1 drugs for employees cost $250M a year
